Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)

Key Points

• Investors bought 20,849 call options on Organon on Friday, a roughly 537% increase versus typical call volume.
• Shares jumped about 25.5% to $8.67 on heavy trading (22.36M shares vs. average 5.19M), signaling strong short-term market interest.
• Organon missed Q4 EPS ($0.63 vs. $0.73 consensus) with revenue down 5.3% year-over-year, and analysts hold an average rating of "Reduce" with a $8.50 price target.

Organon & Co. (NYSE:OGN - Get Free Report) was the target of some unusual options trading activity on Friday. Investors bought 20,849 call options on the company. This represents an increase of approximately 537% compared to the typical volume of 3,274 call options.

Organon & Co. Stock Up 25.5%

Shares of NYSE OGN traded up $1.76 during trading on Friday, hitting $8.67. The stock had a trading volume of 22,361,115 shares, compared to its average volume of 5,185,998. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.24. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23. The company has a market capitalization of $2.26 billion, a PE ratio of 12.22, a PEG ratio of 0.54 and a beta of 0.67. The firm has a fifty day moving average of $6.93 and a two-hundred day moving average of $7.78.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the previous year, the company earned $0.90 EPS. The business's revenue was down 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were paid a $0.02 dividend. The ex-dividend date was Monday, February 23rd. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. Organon & Co.'s dividend payout ratio is presently 11.27%.

Institutional Trading of Organon & Co.

Institutional investors have recently made changes to their positions in the company. Sector Gamma AS bought a new stake in shares of Organon & Co. in the 3rd quarter worth $5,807,000. Gotham Asset Management LLC boosted its holdings in shares of Organon & Co. by 37.2% in the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company's stock worth $39,657,000 after buying an additional 1,007,691 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company's stock worth $383,715,000 after buying an additional 3,650,860 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Organon & Co. in the 3rd quarter worth about $2,000,000. Finally, Douglas Lane & Associates LLC boosted its holdings in shares of Organon & Co. by 40.5% in the 3rd quarter. Douglas Lane & Associates LLC now owns 443,876 shares of the company's stock worth $4,741,000 after buying an additional 127,924 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on OGN. Barclays boosted their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research note on Tuesday, February 24th. Wall Street Zen lowered shares of Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Finally, Zacks Research lowered shares of Organon & Co. from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $8.50.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.